-The Times of India The Supreme Court on Monday rejected pharma giant Novartis AG's plea to preserve its patent over a life-saving cancer drug, Glivec, drawing a huge sigh of relief from thousands of patients in India and in dozens of developing countries as the fear of an almost 15-fold escalation of drug costs receded. It is the biggest setback for multinational pharma companies, which have been denied patent protection...
More »SEARCH RESULT
Domestic pharma lauds apex court verdict-Reghu Balakrishnan
-The Business Standard Patients' lobbies cheer ruling on anti-cancer drug Glivec, as affordability and access to life-saving drugs get a leg-up Though the India office here of Swiss pharma giant Novartis wore a gloomy look following the Supreme Court rejection of its Glivec patent application, Indian pharmaceutical companies and patients' associations are in celebration mood. D G Shah, secretary general, The Indian Pharmaceutical Alliance (IPA), comprising leading research-based Indian pharma companies, said,...
More »Supreme Court imposes Rs 100 crore fine on Sterlite Industries
-Reuters India's top court imposed a fine of Rs 100 crore ($18.40 million) on Sterlite Industries for polluting environment through its copper smelting plant in Tamil Nadu. The case is unrelated to a separate order that has shut the Tuticorin plant, India's largest, since last week following complaints of a gas leak. Despite the fine, the Supreme Court overruled an earlier order from the Madras High Court to shut down the plant over...
More »Novartis loses patent battle in SC
-The Business Standard Court denies Swiss drug firm patent protection for its anti-cancer drug Glivec; domestic industry hails verdict The Supreme Court on Monday dismissed Novartis AG's appeal for patent protection of its anti-cancer drug, Glivec, putting an end to a seven-year battle between the Swiss drug maker, several domestic generic manufacturers, as well as patient groups fighting for affordable medicines. A Bench of judges Aftab Alam and Ranjana Desai said in a...
More »Supreme Court's Glivec ruling will ruin innovation
-The Economic Times Extension of life is priceless. Simply priceless." These were the words of Venkat Krishnan (name changed) to Novartis after receiving treatment with Glivec for about two years. Following his diagnosis with chronic myeloid leukaemia (CML), Venkat married his college sweetheart against the wishes of her family. After all, the prognosis in those days for people suffering from CML was not promising. Taking interferon, a powerful immune therapy, was the...
More »